Stance Capital’s Biogen BIIB Stock Holding History

Stance Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$14.8K	Buy	+81	New	+$14.9K	0.01%	220
2025 Q1	–	Sell	-3	Closed	-$459	–	76
2024 Q4	$459	Buy	+3	New	+$506	﹤0.01%	245

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Stance Capital's BIIB Position: Q1 2026 in Review

Stance Capital opened a new position in Biogen (BIIB) in Q1 2026: 81 shares worth $14.8K. The stake represents 0.01% of the portfolio and ranks #220 among its holdings. This is a return to the name: Stance Capital previously reported a position in BIIB as recently as Q4 2024.

Stance Capital first reported a position in BIIB in Q4 2024 and has held it in 2 quarters since. 1,004 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

Stance Capital held 81 shares of Biogen worth $14.8K as of Q1 2026.
Biogen was a new Stance Capital position in Q1 2026.
Biogen made up 0.01% of Stance Capital's portfolio in Q1 2026, its #220 holding.
Stance Capital first reported a position in Biogen in Q4 2024 and has held it in 2 quarters since.
1,004 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Stance Capital's 13F filing for Q1 2026, filed 14 May 2026.